BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18624839)

  • 1. Palmoplantar psoriasis: a paradoxical adverse reaction induced by adalimumab.
    Bordel-Gómez MT; Sánchez-Estella J; Martínez-González O; Cardeñoso-Alvarez ME
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):444-5. PubMed ID: 18624839
    [No Abstract]   [Full Text] [Related]  

  • 2. First case report of adalimumab-induced psoriasis in Crohn's disease.
    Harris MD; Richards R
    Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
    [No Abstract]   [Full Text] [Related]  

  • 3. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management.
    Papadavid E; Gazi S; Dalamaga M; Stavrianeas N; Ntelis V
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):380-2. PubMed ID: 18269613
    [No Abstract]   [Full Text] [Related]  

  • 4. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
    Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
    Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
    Egnatios G; Warthan MM; Pariser R; Hood AF
    J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764
    [No Abstract]   [Full Text] [Related]  

  • 6. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers.
    El Shabrawi-Caelen L; La Placa M; Vincenzi C; Haidn T; Muellegger R; Tosti A
    Inflamm Bowel Dis; 2010 Feb; 16(2):182-3. PubMed ID: 19462433
    [No Abstract]   [Full Text] [Related]  

  • 7. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
    Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
    Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-α inhibitor (adalimumab) induced psoriasis: a case report.
    Al-Mutairi A; Elkashlan M; Al-Fayed HM; Swayed M
    Australas J Dermatol; 2012 May; 53(2):157. PubMed ID: 22571571
    [No Abstract]   [Full Text] [Related]  

  • 9. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.
    Perman MJ; Lovell DJ; Denson LA; Farrell MK; Lucky AW
    Pediatr Dermatol; 2012; 29(4):454-9. PubMed ID: 21995665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
    Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
    J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
    [No Abstract]   [Full Text] [Related]  

  • 11. [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease].
    Avila Alvarez A; García-Alonso L; Solar Boga A; García-Silva J
    An Pediatr (Barc); 2009 Mar; 70(3):278-81. PubMed ID: 19409245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of psoriasis with adalimumab.
    Pitarch G; Sanchez-Carazo JL; Mahiques L; Perez-Ferriols MA; Fortea JM
    Clin Exp Dermatol; 2007 Jan; 32(1):18-22. PubMed ID: 17305904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab desensitization after anaphylactic reaction.
    Quercia O; Emiliani F; Foschi FG; Stefanini GF
    Ann Allergy Asthma Immunol; 2011 Jun; 106(6):547-8. PubMed ID: 21624763
    [No Abstract]   [Full Text] [Related]  

  • 15. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.
    Piérard GE; Piérard-Franchimont C; Szepetiuk G; Paquet P; Quatresooz P
    Expert Opin Biol Ther; 2010 Aug; 10(8):1197-208. PubMed ID: 20560729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab in the management of palmoplantar psoriasis.
    Ghate JV; Alspaugh CD
    J Drugs Dermatol; 2009 Dec; 8(12):1136-9. PubMed ID: 20027943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases.
    Ubriani R; Van Voorhees AS
    Arch Dermatol; 2007 Feb; 143(2):270-2. PubMed ID: 17310016
    [No Abstract]   [Full Text] [Related]  

  • 18. "Paradoxical" adverse effects caused by anti-tumor necrosis factor-α biological drugs: appearance of psoriasis in a patient treated with infliximab for rheumatoid arthritis.
    Satriano RA; Abbate G; Esposito S; Cassaglia B; Piccolo V; Baroni A
    Indian J Dermatol Venereol Leprol; 2011; 77(4):536. PubMed ID: 21727719
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease.
    Salgueiro P; Lago P; Pedroto I
    J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.